Medical Economics September 6, 2024
By improving health outcomes and avoiding costly obesity-related complications, GLP-1s can significantly reduce the overall cost of health care.
Roughly 12% of American adults have tried a “GLP-1” drug, the revolutionary class of medications that can treat obesity and diabetes. That percentage is set to soar thanks to cheaper generic versions of early GLP-1 drugs now hitting the market.
Teva Pharmaceuticals just launched the first generic GLP-1 available to Americans. It’s a generic version of the diabetes treatment Victoza — which recently went off-patent — and is expected to be 13.6% cheaper than the brand-name drug before rebates. After factoring in discounts, brand-name anti-obesity drugs already sell for 48% to 79% below their nominal “list” prices, so Teva’s drug will...
Today's Sponsors
Today's Sponsor